Medicrea H1 Revenue Rises 7% to 14.8 Million Euros

Share Article

Medical device company Medicrea announces their H1 Sales for 2016 are 7% higher than their H1 Sales from 2015, rising from €13.8 million to €14.8 million with the consistent acceleration of sales from their patient-specific UNiD technology.

News Image
Medicrea has experienced a consistent acceleration in the global adoption of its patient-specific UNiD™ technology throughout the first half of 2016, especially in the US market.

The Medicrea Group (Alternext Paris: FR0004178572 - ALMED), PEA- PME eligible, pioneering the development and manufacture of patient-specific analytical services and implant solutions for the treatment of spinal conditions, announces sales for the first half of 2016.

Medicrea First Half Sales:

H1 2015 Sales = €13.8 million    
H1 2016 Sales = €14.8 million
Increase = +7%

Movements in exchange rates had no significant impact on the evolution of turnover.

The Group posted sales growth of 7% in H1 2016 compared to the same period in 2015. In France, its most established market, Medicrea continues to gain market share with a 20% increase in revenue over the period, to €2.8 million. In the US, where the Group generates over 60% of its business, sales increased by 13% compared to H1 2015, at €9 million.

"We are seeing a clear momentum in the markets where we operate through our subsidiaries, but our progress has slowed in countries where we are not present directly or are currently suffering fluctuations in economic conditions (notably Brazil). Medicrea will strengthen its commercial position in these territories, in particular by adapting distribution strategies used for each market," indicates Denys Sournac, President and CEO.

Medicrea has experienced a consistent acceleration in the global adoption of its patient-specific UNiD™ technology throughout the first half of 2016, especially in the US market.

“The number of UNiD™ Rod cases in the US during the first half of 2016 has more than doubled compared to the previous year. We believe we are starting to gain real traction with mounting clinical and media attention to the technology compiled in this video. Surgeons and healthcare providers know the immediate benefits of the patient-specific technology and are now beginning to see the longer-term clinical and cost advantages of personalized spinal treatment,” adds Denys Sournac.

Today, Medicrea’s UNiD™ Lab has collaborated with a growing number of spinal surgeons for over 800 UNiD™ surgeries worldwide at an increasing pace of more than 70 UNiD™ surgeries per month.

Denys Sournac continues, “The second half of 2016 is promising. We are beginning to strategically introduce UNiD™ directly into leading markets with the first-ever PASS LP® + UNiD™ case successfully performed in Germany this April. We are also combining our Group resources in France with preparations underway to move, in the next quarter, into our newly-built facilities which will bring across all of our manufacturing capabilities from La Rochelle directly to our development teams and support functions’ doorstep in the Lyon region.”

Next publication:
Results for the 1st half of 2016: September 8, after market.

About Medicrea (
The Medicrea Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a $10 billion market, Medicrea operates with 150 employees, including 40 at its Medicrea USA Corp. subsidiary based in New York City.

The Company enjoys an excellent and ever-improving innovator reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons. The products developed and patented by Medicrea provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.

Medicrea has also become a pioneer and global leader in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiD™ rod). In addition, their lumbar interbody osteosynthesis cages (UNiD™ ALIF cage) are made to measure with the use of a 3D printer.

The Group’s headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as distribution subsidiaries in the USA, the UK, Germany and France.

Connect with Medicrea:

Contacts: Medicrea
Denys Sournac, Founder, Chairman and CEO

Fabrice Kilfiger, Chief Financial Officer
Tel: +33 (0)4 72 01 87 87

Medicrea is listed on ALTERNEXT Paris ISIN: FR 0004178572 – Ticker: ALMED

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Russell Ward
Follow >
The Confluence
Like >
Visit website